Vertex Hit With Class Action Over Hepatitis Drug

Law360, New York (March 14, 2008, 12:00 AM EDT) -- Vertex Pharmaceuticals Inc. has been hit with a class action that accuses the company of concealing critical trial data about telaprevir, a drug used to treat hepatitis C, and misleading people into purchasing stocks that tumbled once the information was made public.

The complaint, filed in the U.S. District Court for the District of Massachusetts, alleges that Vertex made false and misleading statements about the development of telaprevir, also called VX-950, a hepatitis C protease inhibitor, touting the drug's prospects while withholding unfavorable results of a...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.